Skip to main content
CSPC Pharmaceutical Group Limited logo

CSPC Pharmaceutical Group Limited — Investor Relations & Filings

Ticker · 1093 ISIN · US12591J1088 LEI · 529900M3XQCW234H8O91 HKEX Manufacturing
Open in API
Filings indexed 1,527 across all filing types
Latest filing 2012-12-04 Capital/Financing Update
Country HK Hong Kong
Listing HKEX 1093

About CSPC Pharmaceutical Group Limited

https://www.cspc.com.hk/en/global/home.…

CSPC Pharmaceutical Group Limited is a comprehensive enterprise specializing in the research, development, manufacturing, and sale of pharmaceutical products. The company operates across two main segments: finished drugs and bulk drugs. It emphasizes innovation and new drug development, evidenced by substantial R&D investment, to produce high-quality, effective, and reliable medicines. Its portfolio includes key innovative products such as NBP (soft capsules and injections), Oulaining, and Enxi, which are among its top-selling drugs.

Recent filings

Filing Released Lang Actions
Monthly return of equity issuer on movements in securities for the month ended 30 November 2012
Capital/Financing Update Classification · 95% confidence The document is titled 'Monthly Return of Equity Issuer on Movements in Securities' for the month ended 30/11/2012, submitted to the Hong Kong Exchanges and Clearing Limited. It details movements in authorized share capital, issued share capital, share options, warrants, convertibles, and other share-related transactions. The content focuses on changes in the company's capital structure and share issuance activities during the month. There are no financial statements, earnings data, management discussion, or audit information. The document is a regulatory filing reporting monthly share capital movements, typical of a capital or financing update. Therefore, the most appropriate classification is Capital/Financing Update (CAP). The document length is substantial and contains detailed data, not just an announcement or certification, so it is not RNS or RPA.
2012-12-04 English
UNAUDITED RESULTS FOR THE NINE MONTHS ENDED 30 SEPTEMBER 2012
Interim / Quarterly Report Classification · 100% confidence The document is titled 'UNAUDITED RESULTS FOR THE NINE MONTHS ENDED 30 SEPTEMBER 2012' and contains detailed financial statements including a consolidated income statement, segment information, and a business review for the nine-month period ending 30 September 2012. It explicitly states the results are unaudited and covers a period shorter than a full fiscal year (nine months). The presence of actual financial data and analysis for a period less than a full year aligns with the definition of an Interim / Quarterly Report (IR). The document is 7557 characters long, which is sufficient to be a full report rather than a brief announcement. Therefore, the appropriate classification is Interim / Quarterly Report (IR). 9M 2012
2012-11-30 English
DATE OF BOARD MEETING
Regulatory Filings Classification · 95% confidence The document is a short announcement from China Pharmaceutical Group Limited stating the date of a board meeting to approve the unaudited third quarterly results for the nine months ended 30 September 2012. It does not contain the actual financial results or detailed financial data, but merely announces the upcoming board meeting and the agenda item. The document length is only 1301 characters, which is quite short and fits the pattern of an announcement rather than a full report. According to the MENU VS MEAL RULE, this is an announcement related to a report (the quarterly results) but not the report itself. Therefore, it should be classified as a Regulatory Filing (RNS), which is the fallback category for such announcements that do not fit other specific categories.
2012-11-20 English
Monthly return of equity issuer on movements in securities for the month ended 31 October 2012
Share Issue/Capital Change Classification · 95% confidence The document is titled 'Monthly Return of Equity Issuer on Movements in Securities' for the month ended 31/10/2012, submitted to the Hong Kong Exchanges and Clearing Limited. It details movements in authorized and issued share capital, including ordinary shares, preference shares, share options, warrants, convertibles, and other agreements to issue shares. The content focuses on changes in share capital and securities movements rather than financial performance, earnings, or management commentary. It is a regulatory filing reporting share capital changes and securities movements for a listed issuer. The document is lengthy (15,000 characters) and contains detailed data on share capital movements, which is typical for a regulatory filing related to share capital changes. This fits best with the category 'Share Issue/Capital Change' (SHA), which covers announcements regarding new share issues, stock splits, or other capital changes.
2012-11-05 English
CONTINUING CONNECTED TRANSACTION- MUTUAL SUPPLY FRAMEWORK AGREEMENT WITH SPG
Regulatory Filings Classification · 95% confidence The document is an announcement regarding a continuing connected transaction under the Listing Rules of the Hong Kong Stock Exchange. It details a Mutual Supply Framework Agreement between the company and a connected person (SPG), including historical figures, proposed annual caps, reasons for the agreement, and implications under the Listing Rules. The document is structured as a formal announcement with no financial statements or detailed financial performance data. It is not an annual report, interim report, earnings release, or audit report. It is not a regulatory filing in the sense of officer certifications or compliance documents, but a specific announcement about connected transactions subject to reporting and announcement requirements under Chapter 14A of the Listing Rules. This type of document is best classified as a Regulatory Filing (RNS) because it is a general regulatory announcement about continuing connected transactions that do not fit into other specific categories like capital updates or management changes.
2012-11-01 English
Next Day Disclosure Return
Share Issue/Capital Change Classification · 100% confidence The document is a disclosure return related to changes in issued share capital and share buybacks for a listed issuer, China Pharmaceutical Group Limited. It includes detailed information about share issues, repurchases, and the percentage changes in issued share capital, referencing specific listing rules and regulatory requirements. The content focuses on capital changes rather than financial results, management, or other report types. This matches the definition of a Share Issue/Capital Change filing, which covers announcements regarding new share issues, stock splits, or other capital changes. The document length is over 6000 characters and contains substantive data, confirming it is not merely an announcement of a report but the actual disclosure itself.
2012-10-29 English

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.